{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:14:06Z","timestamp":1790108046129,"version":"4.0.1"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.psychres.2025.116575","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:02:43Z","timestamp":1748800963000},"page":"116575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Targeting of inflammation and prostaglandins by nonsteroidal anti-inflammatory drugs in schizophrenia: A narrative review"],"prefix":"10.1016","volume":"351","author":[{"given":"Hayder M.","family":"Al-kuraishy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-6790","authenticated-orcid":false,"given":"Hamdoon A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-3849","authenticated-orcid":false,"given":"Ghassan M.","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid S.","family":"Jabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2025.116575_bib0001","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10787-023-01163-7","article-title":"Long-term use of metformin and Alzheimer\u2019s disease: beneficial or detrimental effects","volume":"31","author":"Al-Kuraishy","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102084","article-title":"The link between Alzheimer disease and metabolic syndrome: a mutual relationship and long rigorous investigation","author":"Al-Kuraishy","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.psychres.2025.116575_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22243","article-title":"Kynurenine pathway in type 2 diabetes: role of metformin","volume":"85","author":"Al-Qahtani","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0004","first-page":"1","article-title":"The probable role of tissue plasminogen activator\/neuroserpin axis in Alzheimer\u2019s disease: a new perspective","author":"Ali","year":"2023","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.psychres.2025.116575_bib0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10787-023-01192-2","article-title":"A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson\u2019s disease: beneficial or detrimental effects","volume":"31","author":"Alrouji","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.771144","article-title":"Inflammation and JNK\u2019s role in niacin-GPR109A diminished flushed effect in microglial and neuronal cells with relevance to schizophrenia","volume":"12","author":"Ansarey","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/00325481.2021.2006514","article-title":"Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?","volume":"134","author":"Ansari","year":"2022","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.psychres.2025.116575_bib0008","first-page":"1","article-title":"Acetaminophen as adjuvant to risperidone in chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial","volume":"13","author":"Arabzadeh","year":"2018","journal-title":"Iran. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0009","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(02)01443-9","article-title":"Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients","volume":"53","author":"Arvindakshan","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0010","article-title":"Aspirin inclusion in antipsychotic treatment on severity of symptoms in schizophrenia: a randimized clinical trial","volume":"11","author":"Attari","year":"2017","journal-title":"Iran. J. Psychiatry Behav. Sci. Psychiatry Behav. Sci."},{"key":"10.1016\/j.psychres.2025.116575_bib0011","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41398-021-01671-6","article-title":"Worldwide prevalence of suicidal ideation and suicide plan among people with schizophrenia: a meta-analysis and systematic review of epidemiological surveys","volume":"11","author":"Bai","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-022-01087-8","article-title":"Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0090-6980(02)00031-X","article-title":"Prostaglandins and other lipid mediators in Alzheimer\u2019s disease","volume":"68","author":"Bazan","year":"2002","journal-title":"Prostaglandins. Other Lipid Mediat."},{"key":"10.1016\/j.psychres.2025.116575_bib0014","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1749-6632.2012.06638.x","article-title":"Autoimmune diseases and infections as risk factors for schizophrenia","volume":"1262","author":"Benros","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.psychres.2025.116575_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.14712\/fb2017063010013","article-title":"The effect of ibuprofen on cytokine production by mononuclear cells from schizophrenic patients","volume":"63","author":"Bessler","year":"2017","journal-title":"Folia Biol."},{"key":"10.1016\/j.psychres.2025.116575_bib0016","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/neuro.08.014.2009","article-title":"Early-life programming of later-life brain and behavior: a critical role for the immune system","volume":"3","author":"Bilbo","year":"2009","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.psychres.2025.116575_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114147","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective","volume":"180","author":"Bindu","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0018","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1017\/S0033291719001685","article-title":"Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis","volume":"49","author":"Bora","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2025.116575_bib0019","first-page":"646","article-title":"The cannabinoid CB1 receptor in schizophrenia","volume":"6","author":"Borgan","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci. NeuroimAging"},{"key":"10.1016\/j.psychres.2025.116575_bib0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10787-014-0211-2","article-title":"Origins and impact of the term \u2018NSAID","volume":"22","author":"Buer","year":"2014","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0021","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4103\/1673-5374.165219","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and neuroprotection in the elderly: a view from the mitochondria","volume":"10","author":"Calvo-Rodr\u00edguez","year":"2015","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0022","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neubiorev.2021.01.018","article-title":"Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Cao","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psychres.2025.116575_bib0023","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuropharm.2018.11.026","article-title":"Distinct influence of COX-1 and COX-2 on neuroinflammatory response and associated cognitive deficits during high altitude hypoxia","volume":"146","author":"Chauhan","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0024","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.7150\/thno.63396","article-title":"Role of prostaglandin E2 in tissue repair and regeneration","volume":"11","author":"Cheng","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.psychres.2025.116575_bib0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1089\/neu.2011.1754","article-title":"Interstitial F2-isoprostane 8-Iso-PGF2\u03b1 as a biomarker of oxidative stress after severe human traumatic brain injury","volume":"29","author":"Clausen","year":"2012","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.psychres.2025.116575_bib0026","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1038\/s41380-020-0829-y","article-title":"Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis","volume":"26","author":"Conen","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0027","doi-asserted-by":"crossref","first-page":"8493","DOI":"10.3390\/ijms23158493","article-title":"Tryptophan metabolism in depression: a narrative review with a focus on serotonin and kynurenine pathways","volume":"23","author":"Correia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.psychres.2025.116575_bib0028","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v67n0408","article-title":"Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs","volume":"67","author":"Correll","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104606","article-title":"Hyper\/neuroinflammation in COVID-19 and suicide etiopathogenesis: hypothesis for a nefarious collision?","volume":"136","author":"Costanza","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psychres.2025.116575_bib0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2017.04.033","article-title":"Endocannabinoid modulation of dopamine neurotransmission","volume":"124","author":"Covey","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0031","series-title":"Phospholipases in Physiology and Pathology","first-page":"161","article-title":"Phospholipase A2 as a modulator of infection, inflammation, and immunity","author":"Das","year":"2023"},{"key":"10.1016\/j.psychres.2025.116575_bib0032","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1007\/s12035-022-02976-3","article-title":"Linking inflammation, aberrant glutamate-dopamine interaction, and post-synaptic changes: translational relevance for schizophrenia and antipsychotic treatment: a systematic review","volume":"59","author":"de Bartolomeis","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.psychres.2025.116575_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-015-0473-7","article-title":"Poly (I: C) increases the expression of mPGES-1 and COX-2 in rat primary microglia","volume":"13","author":"de Oliveira","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.psychres.2025.116575_bib0034","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/glia.24221","article-title":"Emerging evidence for astrocyte dysfunction in schizophrenia","volume":"70","author":"de Oliveira Figueiredo","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.psychres.2025.116575_bib0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ijnp\/pyx092","article-title":"Studies on prostaglandin-endoperoxide synthase 1: lower levels in schizophrenia and after treatment with antipsychotic drugs in conjunction with aspirin","volume":"21","author":"Dean","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0036","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3390\/ph3103101","article-title":"Endocannabinoids and schizophrenia","volume":"3","author":"Desfoss\u00e9s","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.psychres.2025.116575_bib0037","doi-asserted-by":"crossref","first-page":"422","DOI":"10.9758\/cpn.2018.16.4.422","article-title":"From gut to brain: alteration in inflammation markers in the brain of dextran sodium sulfate-induced colitis model mice","volume":"16","author":"Do","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.psychres.2025.116575_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032215","article-title":"Chemokine dysregulation and neuroinflammation in schizophrenia: a systematic review","volume":"24","author":"Ermakov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.psychres.2025.116575_bib0039","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s40473-020-00207-4","article-title":"Inflammatory pathways in psychiatric disorders: the case of schizophrenia and depression","volume":"7","author":"Feng","year":"2020","journal-title":"Curr. Behav. Neurosci. Rep."},{"key":"10.1016\/j.psychres.2025.116575_bib0040","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mp.2012.110","article-title":"Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia","volume":"18","author":"Fillman","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0041","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1172\/JCI83844","article-title":"Prostaglandin-dependent modulation of dopaminergic neurotransmission elicits inflammation-induced aversion in mice","volume":"126","author":"Fritz","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.psychres.2025.116575_bib0042","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/nn.4399","article-title":"Gene expression elucidates functional impact of polygenic risk for schizophrenia","volume":"19","author":"Fromer","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.psychres.2025.116575_bib0043","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S1461145709990770","article-title":"Autoantibodies from schizophrenia patients induce cerebral cox-1\/iNOS mRNA expression with NO\/PGE2\/MMP-3 production","volume":"13","author":"Ganzinelli","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0044","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/nu15051195","article-title":"Association between arachidonic acid and the risk of schizophrenia: a cross-national study and Mendelian randomization analysis","volume":"15","author":"Gao","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.psychres.2025.116575_bib0045","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0046","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.psychres.2025.116575_bib0047","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fnins.2019.00303","article-title":"Chronic microglial activation in the GFAP-IL6 mouse contributes to age-dependent cerebellar volume loss and impairment in motor function","volume":"13","author":"Gyengesi","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.psychres.2025.116575_bib0048","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1021\/jm500535j","article-title":"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents","volume":"57","author":"Hameed","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.psychres.2025.116575_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/2043808719865693","article-title":"Prediction of disability in schizophrenia: symptoms, cognition, and self-assessment","volume":"10","author":"Harvey","year":"2019","journal-title":"J. Exp. Psychopathol."},{"key":"10.1016\/j.psychres.2025.116575_bib0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1017\/S109285292000200X","article-title":"Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice","volume":"27","author":"Hauser","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.psychres.2025.116575_bib0051","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1073\/pnas.94.4.1500","article-title":"Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain","volume":"94","author":"Heyser","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.psychres.2025.116575_bib0052","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(77)92228-0","article-title":"Schizophrenia as a prostaglandin deficiency disease","volume":"309","author":"Horrobin","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2025.116575_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-020-01337-0","article-title":"Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms","volume":"19","author":"Hsu","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.psychres.2025.116575_bib0054","first-page":"37","article-title":"From madness to mental illness: on narratives of \u2018schizophrenia\u2019through the ages","volume":"88","author":"Hudson","year":"2020","journal-title":"Univ. West Ont. Med. J."},{"key":"10.1016\/j.psychres.2025.116575_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/etm.2021.10197","article-title":"Magnetic resonance imaging in schizophrenia: luxury or necessity?","volume":"22","author":"Iliuta","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.psychres.2025.116575_bib0056","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00702-020-02188-w","article-title":"Genetic and environmental factors of schizophrenia and autism spectrum disorder: insights from twin studies","volume":"127","author":"Imamura","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.psychres.2025.116575_bib0057","doi-asserted-by":"crossref","first-page":"442","DOI":"10.22270\/jddt.v9i1-s.2287","article-title":"Non-steroidal anti-inflammatory drugs: an overview","volume":"9","author":"Jahnavi","year":"2019","journal-title":"J. Drug Deliv. Ther."},{"key":"10.1016\/j.psychres.2025.116575_bib0058","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12974-020-1703-1","article-title":"Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception","volume":"17","author":"Jang","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.psychres.2025.116575_bib0059","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fpsyt.2019.00131","article-title":"Autoimmune diseases and psychotic disorders","volume":"10","author":"Jeppesen","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2020.08.028","article-title":"Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders\u2013A comprehensive systematic review and meta-analysis","volume":"90","author":"Jeppesen","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.psychres.2025.116575_bib0061","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/schbul\/sbac098","article-title":"Cerebrospinal fluid and blood biomarkers of neuroinflammation and blood-brain barrier in psychotic disorders and individually matched healthy controls","volume":"48","author":"Jeppesen","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2025.116575_bib0062","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pnpbp.2012.06.003","article-title":"Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat","volume":"39","author":"Johansson","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0063","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00406-016-0749-7","article-title":"Oxidative stress in drug-na\u00efve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders","volume":"268","author":"Jordan","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2025.116575_bib0064","first-page":"1","article-title":"Endocannabinoid system components: overview and tissue distribution","author":"Joshi","year":"2019","journal-title":"Recent Adv. Cannabinoid Physiol. Pathol."},{"key":"10.1016\/j.psychres.2025.116575_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103589","article-title":"Inhibition of endocannabinoid metabolism by the metabolites of ibuprofen and flurbiprofen","volume":"9","author":"Karlsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.psychres.2025.116575_bib0066","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0269881112467089","article-title":"A review of anti-inflammatory agents for symptoms of schizophrenia","volume":"27","author":"Keller","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0067","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1093\/schbul\/sbac107","article-title":"R\u00fcdin\u2019s 1916 monograph: on the inheritance and primary origin of dementia praecox","volume":"48","author":"Kendler","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2025.116575_bib0068","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1042\/EBC20190086","article-title":"The endocannabinoid system","volume":"64","author":"Kilaru","year":"2020","journal-title":"Essays Biochem."},{"key":"10.1016\/j.psychres.2025.116575_bib0069","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0920-9964(99)00171-1","article-title":"Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics","volume":"44","author":"Kim","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0070","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00406-019-01073-2","article-title":"The impact of inflammation on neurocognition and risk for psychosis: a critical review","volume":"270","author":"Kogan","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2025.116575_bib0071","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14656566.2016.1168400","article-title":"Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse\u2013a population-based study of 16,253 incident patients with schizophrenia","volume":"17","author":"K\u00f6hler","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.psychres.2025.116575_bib0072","doi-asserted-by":"crossref","first-page":"405","DOI":"10.15789\/1563-0625-PON-1974","article-title":"Pathways of neuro-immune communication: past and present time, clinical application","volume":"22","author":"Korneva","year":"2020","journal-title":"Med. Immunol."},{"key":"10.1016\/j.psychres.2025.116575_bib0073","first-page":"42","article-title":"Notes on the history of schizophrenia","volume":"8","author":"Kyziridis","year":"2005","journal-title":"Ger. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0074","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.euroneuro.2006.09.003","article-title":"Non-steroidal anti-inflammatory drugs and the risk of psychosis","volume":"17","author":"Laan","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0076","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1139\/cjpp-2023-0107","article-title":"TLR\/mTOR inflammatory signaling pathway: novel insight for the treatment of schizophrenia","volume":"102","author":"Lashgari","year":"2023","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0077","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.mp.4001819","article-title":"The role of phospholipases A2 in schizophrenia","volume":"11","author":"Law","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0078","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40263-018-0539-z","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention","volume":"32","author":"Leweke","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2025.116575_bib0079","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1007\/s11064-020-03109-9","article-title":"Ibuprofen exerts antiepileptic and neuroprotective effects in the rat model of pentylenetetrazol-induced epilepsy via the COX-2\/NLRP3\/IL-18 pathway","volume":"45","author":"Liu","year":"2020","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fpsyt.2019.00328","article-title":"Schizophrenia, not a psychotic disorder: bleuler revisited","volume":"10","author":"Loch","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0081","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.euroneuro.2018.12.011","article-title":"Neuroinflammation in the dorsolateral prefrontal cortex in elderly chronic schizophrenia","volume":"29","author":"L\u00f3pez-Gonz\u00e1lez","year":"2019","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0082","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1007\/s12035-020-02087-x","article-title":"The role of brain cyclooxygenase-2 (Cox-2) beyond neuroinflammation: neuronal homeostasis in memory and anxiety","volume":"57","author":"L\u00f3pez","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.psychres.2025.116575_bib0083","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1590\/1516-4446-2018-0237","article-title":"Schneider\u2019s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis","volume":"42","author":"Malinowski","year":"2019","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0084","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1017\/S0033291718003057","article-title":"Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies","volume":"49","author":"Marques","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2025.116575_bib0085","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3389\/fphar.2020.01003","article-title":"Dopamine receptor subtypes, physiology and pharmacology: new ligands and concepts in schizophrenia","volume":"11","author":"Martel","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0086","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2011.01.018","article-title":"The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia","volume":"128","author":"Mart\u00ednez-Gras","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0087","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3109\/15622971003758748","article-title":"Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 d-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls","volume":"11","author":"Martins-De-Souza","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0088","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41398-018-0366-5","article-title":"Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study","volume":"9","author":"Martinuzzi","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0089","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41380-020-00951-9","article-title":"The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies","volume":"26","author":"Marx","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0090","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3389\/fphar.2020.01153","article-title":"NSAID\u2013gut microbiota interactions","volume":"11","author":"Maseda","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0091","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41380-019-0502-5","article-title":"The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis","volume":"26","author":"McCutcheon","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0092","doi-asserted-by":"crossref","DOI":"10.3390\/nu14050917","article-title":"Emerging evidence for the widespread role of glutamatergic dysfunction in neuropsychiatric diseases","volume":"14","author":"McGrath","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.psychres.2025.116575_bib0093","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/da.22084","article-title":"Cytokine targets in the brain: impact on neurotransmitters and neurocircuits","volume":"30","author":"Miller","year":"2013","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.psychres.2025.116575_bib0094","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","article-title":"C-reactive protein levels in schizophrenia: a review and meta-analysis","volume":"7","author":"Miller","year":"2014","journal-title":"Clin. Schizophr. Relat. Psychoses."},{"key":"10.1016\/j.psychres.2025.116575_bib0096","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.2174\/1381612827666210804110139","article-title":"Metabolomic connections between schizophrenia, antipsychotic drugs and metabolic syndrome: a variety of players","volume":"27","author":"Molina","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.psychres.2025.116575_bib0097","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s13318-022-00766-9","article-title":"Population pharmacokinetic modelling of acetaminophen and ibuprofen: the influence of body composition, formulation and feeding in healthy adult volunteers","volume":"47","author":"Morse","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.psychres.2025.116575_bib0098","first-page":"31","article-title":"COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence","volume":"11","author":"Mueller","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.psychres.2025.116575_bib0099","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"M\u00fcller","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0100","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/13543784.13.8.1033","article-title":"COX-2 inhibitors as adjunctive therapy in schizophrenia","volume":"13","author":"M\u00fcller","year":"2004","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.psychres.2025.116575_bib0101","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41398-021-01607-0","article-title":"Neuroinflammation in schizophrenia: the role of nuclear factor kappa B","volume":"11","author":"Murphy","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0102","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.912","article-title":"Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Nery","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0103","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2025.116575_bib0104","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.580289","article-title":"Analgesic effect of acetaminophen: a review of known and novel mechanisms of action","volume":"11","author":"Ohashi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0105","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2165\/00003495-200464230-00001","article-title":"NSAID-related psychiatric adverse events: who is at risk?","volume":"64","author":"Onder","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.psychres.2025.116575_bib0106","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41380-018-0220-4","article-title":"Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis","volume":"24","author":"Orlovska-Waast","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0107","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s11033-021-06264-6","article-title":"Molecular mechanisms involved in the prevention and reversal of ketamine-induced schizophrenia-like behavior by rutin: the role of glutamic acid decarboxylase isoform-67, cholinergic, Nox-2-oxidative stress pathways in mice","volume":"48","author":"Oshodi","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.psychres.2025.116575_bib0108","first-page":"614","article-title":"Structural modification of ibuprofen as new NSAIDs via DFT, molecular docking and pharmacokinetics studies","volume":"33","author":"Oyeneyin","year":"2021","journal-title":"Int. J. Adv. Eng. Pure Sci."},{"key":"10.1016\/j.psychres.2025.116575_bib0109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-020-1721-z","article-title":"Effects of inflammation on the kynurenine pathway in schizophrenia\u2014A systematic review","volume":"17","author":"Pedraz-Petrozzi","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.psychres.2025.116575_bib0110","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/15622975.2021.1961501","article-title":"COX-2 pathway is upregulated in ultra-high risk individuals for psychosis","volume":"23","author":"Pereira","year":"2022","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0111","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.3390\/molecules25225388","article-title":"Cyclooxygenase inhibition safety and efficacy in inflammation-based psychiatric disorders","volume":"25","author":"Perrone","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.psychres.2025.116575_bib0112","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/schbul\/sbw221","article-title":"Kynurenic acid in schizophrenia: a systematic review and meta-analysis","volume":"43","author":"Plitman","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2025.116575_bib0113","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1017\/S003329171300295X","article-title":"Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis","volume":"44","author":"Pollak","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2025.116575_bib0114","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archpsyc.55.2.188","article-title":"Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid","volume":"55","author":"Puri","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0115","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.2174\/1381612822666160906160911","article-title":"The microbiota and gut-brain axis: contributions to the immunopathogenesis of schizophrenia","volume":"22","author":"Caso","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.psychres.2025.116575_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112958","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: adjusting prescription to patient features","volume":"150","author":"Ribeiro","year":"2022","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.psychres.2025.116575_bib0117","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2015.07.022","article-title":"Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology","volume":"101","author":"Rojo","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0118","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/2211556011302010073","article-title":"Polyunsaturated fatty acids and their metabolites in neural development and implications for psychiatric disorders","volume":"2","author":"Sakayori","year":"2012","journal-title":"Curr. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0119","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.103.049700","article-title":"Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration","volume":"306","author":"Salzberg-Brenhouse","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.psychres.2025.116575_bib0120","doi-asserted-by":"crossref","first-page":"R1345","DOI":"10.1152\/ajpregu.00268.2005","article-title":"Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA\/GABAA dysregulation and impaired spatial learning","volume":"290","author":"Samuelsson","year":"2006","journal-title":"Am. J. Physiol. Integr. Comp. Physiol."},{"key":"10.1016\/j.psychres.2025.116575_bib0121","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1007\/s00213-022-06263-w","article-title":"Acute administration of ibuprofen increases serum concentration of the neuroprotective kynurenine pathway metabolite, kynurenic acid: a pilot randomized, placebo-controlled, crossover study","volume":"239","author":"Savitz","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0122","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.psychres.2025.116575_bib0123","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbi.2020.04.021","article-title":"Increased densities of T and B lymphocytes indicate neuroinflammation in subgroups of schizophrenia and mood disorder patients","volume":"88","author":"Schlaaff","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.psychres.2025.116575_bib0124","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2174\/1573406411309060002","article-title":"Mechanisms of involvement of eicosanoids and their precursors in the pathophysiology and treatment of schizophrenia","volume":"9","author":"Schmidt","year":"2013","journal-title":"Med. Chem."},{"key":"10.1016\/j.psychres.2025.116575_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2022.09.001","article-title":"The role of inflammation in the pathophysiology of depression and suicidal behavior: implications for treatment","volume":"107","author":"Serafini","year":"2023","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.psychres.2025.116575_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109737","article-title":"Mortality risk following acute coronary syndrome among patients with schizophrenia: a meta-analysis","volume":"96","author":"Shao","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0127","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.4103\/psychiatry.IndianJPsychiatry_527_18","article-title":"Obsessive\u2013compulsive disorder comorbid with schizophrenia and bipolar disorder","volume":"61","author":"Sharma","year":"2019","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0128","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.neuroimage.2010.05.009","article-title":"Phospholipase A2 activity is associated with structural brain changes in schizophrenia","volume":"52","author":"Smesny","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.psychres.2025.116575_bib0129","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia-data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0130","article-title":"Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis","volume":"72","author":"Sommer","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0131","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2025.116575_bib0132","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fpsyt.2020.00613","article-title":"Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia","volume":"11","author":"Sonnenschein","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0133","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105439","article-title":"Deciphering the mechanisms of reciprocal regulation or interdependence at the cannabinoid CB1 receptors and cyclooxygenase-2 level: effects on mood, cognitive implications, and synaptic signaling","volume":"155","author":"Stachowicz","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psychres.2025.116575_bib0134","first-page":"363","article-title":"Innate immune cells and C-reactive protein in acute first-episode psychosis and schizophrenia: relationship to psychopathology and treatment","volume":"46","author":"Steiner","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2025.116575_bib0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-2007-977714","article-title":"The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study","volume":"40","author":"Stolk","year":"2007","journal-title":"PharmacoPsychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0136","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00702-022-02566-6","article-title":"Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial","volume":"130","author":"Strube","year":"2023","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.psychres.2025.116575_bib0137","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111644","article-title":"The role of thromboxane in the course and treatment of ischemic stroke","volume":"22","author":"Szczuko","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.psychres.2025.116575_bib0138","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.psychres.2011.09.026","article-title":"Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia","volume":"196","author":"Tang","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0139","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319870033","article-title":"Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia","volume":"9","author":"Taylor","year":"2019","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0140","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1016\/j.jmb.2020.07.020","article-title":"Integral membrane enzymes in eicosanoid metabolism: structures, mechanisms and inhibitor design","volume":"432","author":"Thulasingam","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.psychres.2025.116575_bib0141","first-page":"309","article-title":"Non-opioid analgesics and the endocannabinoid system","volume":"37","author":"Topuz","year":"2020","journal-title":"Balk. Med. J."},{"key":"10.1016\/j.psychres.2025.116575_bib0142","article-title":"Aspirin attenuates hyperoxia-induced acute respiratory distress syndrome (ARDS) by suppressing pulmonary inflammation via the NF-\u03baB signaling pathway","volume":"12","author":"Tung","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0143","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2025.116575_bib0144","doi-asserted-by":"crossref","unstructured":"Upthegrove, R., Khandaker, G.M., 2020. Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Neuroinflammation Schizophr. 49\u201366.","DOI":"10.1007\/7854_2018_88"},{"key":"10.1016\/j.psychres.2025.116575_bib0145","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fphar.2020.00394","article-title":"The cross-talk between the dopaminergic and the immune system involved in schizophrenia","volume":"11","author":"Vidal","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0146","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41386-023-01760-8","article-title":"A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na\u00efve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms","volume":"49","author":"Wang","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0147","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.schres.2018.06.033","article-title":"Autoimmune diseases are associated with an increased risk of schizophrenia: a nationwide population-based cohort study","volume":"202","author":"Wang","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0148","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.euroneuro.2023.04.007","article-title":"A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder","volume":"73","author":"Weiser","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0149","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jamapsychiatry.2022.0407","article-title":"Inflammation and brain structure in schizophrenia and other neuropsychiatric disorders: a Mendelian randomization study","volume":"79","author":"Williams","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108736","article-title":"Mechanisms of endocannabinoid control of synaptic plasticity","volume":"197","author":"Winters","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psychres.2025.116575_bib0151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-018-1999-x","article-title":"Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel mental specialized hospital, central Ethiopia: cross-sectional study","volume":"19","author":"Wubeshet","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2025.116575_bib0152","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2174\/138161208784480144","article-title":"Cyclooxygenase-2 in synaptic signaling","volume":"14","author":"Yang","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.psychres.2025.116575_bib0153","first-page":"64","article-title":"Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia","author":"Yang","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.psychres.2025.116575_bib0154","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.7150\/ijbs.60149","article-title":"The imbalance of PGD2-DPs pathway is involved in the type 2 diabetes brain injury by regulating autophagy","volume":"17","author":"Yang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.psychres.2025.116575_bib0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.14530","article-title":"Prostaglandin-cytokine crosstalk in chronic inflammation","volume":"176","author":"Yao","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0156","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0920-9964(94)90045-0","article-title":"Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition","volume":"13","author":"Yao","year":"1994","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0157","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2174\/1570159X13666151102103305","article-title":"Eicosanoids derived from arachidonic acid and their family prostaglandins and cyclooxygenase in psychiatric disorders","volume":"13","author":"Yui","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.psychres.2025.116575_bib0158","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108327","article-title":"Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain","volume":"241","author":"Z\u00e1dori","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2025.116575_bib0159","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12640-018-9952-9","article-title":"Influence of cyclooxygenase-2 inhibitors on kynurenic acid production in rat brain in vitro","volume":"35","author":"Zakrocka","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.psychres.2025.116575_bib0160","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s43440-023-00460-w","article-title":"The influence of cyclooxygenase inhibitors on kynurenic acid production in rat kidney: a novel path for kidney protection?","volume":"75","author":"Zakrocka","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.psychres.2025.116575_bib0161","doi-asserted-by":"crossref","DOI":"10.5812\/ijpbs-138643","article-title":"Antipsychotic effects of Celecoxib add-on haloperidol in schizophrenia: a randomized double-blind placebo-controlled clinical trial","volume":"18","author":"Zarghami","year":"2024","journal-title":"Iran. J. Psychiatry Behav. Sci."},{"key":"10.1016\/j.psychres.2025.116575_bib0162","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.3390\/cells10112979","article-title":"Endocannabinoid metabolism and traumatic brain injury","volume":"10","author":"Zhu","year":"2021","journal-title":"Cells"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125002239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125002239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:32:36Z","timestamp":1778945556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125002239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":162,"alternative-id":["S0165178125002239"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116575","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting of inflammation and prostaglandins by nonsteroidal anti-inflammatory drugs in schizophrenia: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116575"}}